JP5653917B2 - 神経変性疾患の治療のためのｐｋｃ活性化化合物 - Google Patents

神経変性疾患の治療のためのｐｋｃ活性化化合物 Download PDF

Info

Publication number
JP5653917B2
JP5653917B2 JP2011521235A JP2011521235A JP5653917B2 JP 5653917 B2 JP5653917 B2 JP 5653917B2 JP 2011521235 A JP2011521235 A JP 2011521235A JP 2011521235 A JP2011521235 A JP 2011521235A JP 5653917 B2 JP5653917 B2 JP 5653917B2
Authority
JP
Japan
Prior art keywords
acid
compound
pkc
cyclopropanated
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011521235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529503A5 (enExample
JP2011529503A (ja
Inventor
ネルソン、トマス・ジェイ．
アルコン、デニエル・エル．
Original Assignee
ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート filed Critical ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Publication of JP2011529503A publication Critical patent/JP2011529503A/ja
Publication of JP2011529503A5 publication Critical patent/JP2011529503A5/ja
Application granted granted Critical
Publication of JP5653917B2 publication Critical patent/JP5653917B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/133—Monohydroxylic alcohols containing saturated rings monocyclic
    • C07C31/1333—Monohydroxylic alcohols containing saturated rings monocyclic with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
JP2011521235A 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物 Expired - Fee Related JP5653917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8417208P 2008-07-28 2008-07-28
US61/084,172 2008-07-28
PCT/US2009/051927 WO2010014585A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014182597A Division JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物

Publications (3)

Publication Number Publication Date
JP2011529503A JP2011529503A (ja) 2011-12-08
JP2011529503A5 JP2011529503A5 (enExample) 2012-09-13
JP5653917B2 true JP5653917B2 (ja) 2015-01-14

Family

ID=41136734

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011521235A Expired - Fee Related JP5653917B2 (ja) 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Country Status (6)

Country Link
US (7) US8163800B2 (enExample)
EP (3) EP3403650A3 (enExample)
JP (4) JP5653917B2 (enExample)
CA (2) CA2941035A1 (enExample)
ES (1) ES2683021T3 (enExample)
WO (1) WO2010014585A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016172727A (ja) * 2008-07-28 2016-09-29 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経変性疾患の治療のためのｐｋｃ活性化化合物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
US20140038186A1 (en) * 2010-02-22 2014-02-06 Tapan Kumar Khan Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
WO2012006516A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
DK2701697T3 (da) 2011-04-26 2020-06-29 Retrotope Inc Oxidative nethindesygdomme
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US20140235496A1 (en) 2011-10-05 2014-08-21 Blanchette Rockefeller Neurosciences Drive Stimulus-elicited genomic profile markers of a neurodegenerative condition
JP6563193B2 (ja) * 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｄｃｐｌａのエステル、およびそれを用いた処置の方法
US10821079B2 (en) * 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
WO2014126191A1 (ja) * 2013-02-15 2014-08-21 株式会社西崎創薬研究所 シクロプロパン環を有する不飽和脂肪酸誘導体を含むリン脂質化合物
WO2014145316A1 (en) 2013-03-15 2014-09-18 Alkon Daniel L Methods for identifying neuroprotective pkc activators
ES2927760T3 (es) * 2013-10-18 2022-11-10 Blanchette Rockefeller Neurosciences Inst Esteres halogenados de ácidos grasos insaturados ciclopropanados para su utilización en el tratamiento de las enfermedades neurodegenerativas
MX2016013680A (es) 2014-04-18 2017-07-05 Neurotrope Bioscience Inc Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
US9413754B2 (en) 2014-12-23 2016-08-09 Airwatch Llc Authenticator device facilitating file security
EP3294290A1 (en) 2015-05-11 2018-03-21 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US20180256537A1 (en) 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
US20180311209A1 (en) 2015-10-08 2018-11-01 Cognitive Research Enterprises, Inc. Dosing regimens of pkc activators
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
JP6912072B2 (ja) * 2016-12-14 2021-07-28 国立大学法人山口大学 前頭側頭型認知症の予防又は治療用医薬
WO2018187647A1 (en) 2017-04-06 2018-10-11 Neurotrope Bioscience, Inc. Methods and compositions for treatment of neurological diseases, disorders, or conditions
WO2019222564A1 (en) * 2018-05-18 2019-11-21 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
WO2020118282A1 (en) * 2018-12-07 2020-06-11 The Johns Hopkins University Methods, compositions and kits for treating multiple sclerosis and other disorders
KR20220143931A (ko) 2020-02-21 2022-10-25 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
US20240165075A1 (en) * 2021-02-08 2024-05-23 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
US20250345400A1 (en) * 2022-05-18 2025-11-13 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025056602A1 (en) 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2172771A1 (en) 1995-03-28 1996-09-29 Akiyoshi Tani Method for assaying map kinase
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU2316797A (en) 1996-02-29 1997-09-16 Mount Sinai Hospital Corporation Shc proteins
JPH1090263A (ja) 1996-07-25 1998-04-10 Mclean Hospital Corp:The アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用
AU5994099A (en) 1998-10-01 2000-04-26 Urmas Arumae A novel ret-independent signaling pathway for gdnf
WO2000070099A2 (en) 1999-05-19 2000-11-23 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
AU1630501A (en) 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
WO2001069244A2 (en) 2000-03-10 2001-09-20 Washington University Method for labeling individual cells
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
JP2004500419A (ja) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
EP1299352B1 (en) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
CA2417744A1 (en) 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
HUP0303857A3 (en) 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
AUPR215700A0 (en) 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
JP2004517619A (ja) 2000-12-21 2004-06-17 ノバルティス アクチエンゲゼルシャフト インターロイキン−１関連遺伝子およびタンパク質
EP1358329A2 (en) 2001-02-06 2003-11-05 Incyte Genomics, Inc. Lipid-associated molecules
JP4024554B2 (ja) 2001-02-27 2007-12-19 松下電器産業株式会社 燃料電池発電システム
ES2305234T3 (es) 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US6874208B2 (en) 2001-03-14 2005-04-05 Autoliv Asp, Inc. Anchoring attachment apparatus
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
US20040014678A1 (en) 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
WO2006050475A2 (en) 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
US20090029355A1 (en) 2004-11-15 2009-01-29 Wei-Qin Zhao Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease
US8686177B2 (en) * 2008-03-03 2014-04-01 Rxbio, Inc. LPA receptor agonists and antagonists
US20090182021A1 (en) 2005-08-03 2009-07-16 Nanternet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
EP1934618B1 (en) 2005-10-11 2009-05-13 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
WO2007043998A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2007149985A2 (en) 2006-06-21 2007-12-27 Lexicor Medical Technology, Llc Assessing dementia and dementia-type disorders
JP2008143819A (ja) * 2006-12-08 2008-06-26 Tomoyuki Nishizaki 酸化ストレス誘導細胞死の抑制剤
WO2008100449A2 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
US20100209914A1 (en) 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
CA2941035A1 (en) * 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016172727A (ja) * 2008-07-28 2016-09-29 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経変性疾患の治療のためのｐｋｃ活性化化合物

Also Published As

Publication number Publication date
US20200331875A1 (en) 2020-10-22
EP3403650A3 (en) 2019-02-13
JP2018168170A (ja) 2018-11-01
JP2016172727A (ja) 2016-09-29
US20100022645A1 (en) 2010-01-28
US10696644B2 (en) 2020-06-30
ES2683021T3 (es) 2018-09-24
US9119825B2 (en) 2015-09-01
US8163800B2 (en) 2012-04-24
US20220356161A1 (en) 2022-11-10
EP2328572A1 (en) 2011-06-08
WO2010014585A1 (en) 2010-02-04
US20120149768A1 (en) 2012-06-14
EP3586839A1 (en) 2020-01-01
JP6449186B2 (ja) 2019-01-09
US20240025870A1 (en) 2024-01-25
US10323011B2 (en) 2019-06-18
EP2328572B1 (en) 2018-06-13
US11390596B2 (en) 2022-07-19
EP3403650A2 (en) 2018-11-21
CA2731171C (en) 2016-10-18
US20190270715A1 (en) 2019-09-05
US11820745B2 (en) 2023-11-21
CA2941035A1 (en) 2010-02-04
CA2731171A1 (en) 2010-02-04
US20160060236A1 (en) 2016-03-03
JP2011529503A (ja) 2011-12-08
JP2015042643A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
JP6449186B2 (ja) 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP6446625B2 (ja) 脳卒中の治療法におけるｐｋｃ活性化因子および抗凝血剤
JP6422778B2 (ja) Ｐｋｃアクチベーターおよびその組合せ
US11173140B2 (en) Dosing regimens of PKC activators
US20230235378A1 (en) Lzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon protein levels
JP2015502347A (ja) Ｄｃｐｌａのエステル、およびそれを用いた処置の方法
US20240390324A1 (en) Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
JP2016535012A (ja) 神経変性疾患の治療において使用するためのシクロプロパン化された不飽和脂肪酸のハロゲン化エステル

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140908

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141119

R150 Certificate of patent or registration of utility model

Ref document number: 5653917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees